In Vivo activation of mINK cells with INKmuneTM – Results from a Phase I-II Clinical Trial in Patients with Metastatic, Castration-Resistant Prostate Cancer
Time: 3:30 pm
day: Day 1 PM
Details:
- Discussing interim clinical results from using a tumor cell “psuedokine” to activate and recruit NK cells to target solid tumors in vivo
- Highlighting key considerations when moving NK trials from tertiary to secondary clinical settings
